Evidence map›Paper›PMID 41766908›Full record

ArticleFrontiers in immunology2026

Association between peripheral IFN-γ

Hui Lu, Huijuan Fang, Mengqi Ruan, Zhi Duang, Yan Wang, Wenwen Liu, Qin Wang, Qiang Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hui LuDepartment of Clinical Laboratory, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Huijuan FangDepartment of Clinical Laboratory, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Mengqi RuanDepartment of Clinical Laboratory, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Zhi DuangDepartment of Clinical Laboratory, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Yan WangShaanxi Techshake Biotechnology, Xian, Shaanxi, China.
Wenwen LiuDepartment of Obstetrics and Gynecology, NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Qin WangDepartment of Clinical Laboratory, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Qiang ZhouDepartment of Clinical Laboratory, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1)-based immune checkpoint therapy (ICT), either alone or in combination with tyrosine kinase inhibitors (TKIs) or bevacizumab, benefits a subset of patients with hepatocellular carcinoma (HCC), and reliable predictive biomarkers remain limited. Methods: Between August 2024 and July 2025, 55 HCC patients treated with PD-1-based therapies were included. Objective response rate (ORR) was assessed according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Peripheral cytotoxic lymphocyte subsets and effector functions were profiled by multiparameter flow cytometry. Results: We observed that the ICT plus TKI group exhibited a higher ORR than ICT monotherapy (54.5% vs. 29.4%; n = 22 vs. n = 17), whereas the ORR in the ICT plus bevacizumab group was comparable to ICT monotherapy (37.5% vs. 29.4%; n = 16 vs. n = 17). Compared with ICT monotherapy, patients receiving ICT plus TKI therapy had higher peripheral CD8 Conclusion: These findings support peripheral IFN-γ

Indexed as

B7-H1 AntigenCarcinoma, HepatocellularImmune Checkpoint InhibitorsInterferon-gammaLiver NeoplasmsProgrammed Cell Death 1 ReceptorT-Lymphocytes, CytotoxicAgedBevacizumabFemaleHumansMaleMiddle AgedProtein Kinase InhibitorsTreatment OutcomeB7-H1 AntigenBevacizumabCD274 protein, humanImmune Checkpoint InhibitorsInterferon-gammaPDCD1 protein, humanProgrammed Cell Death 1 ReceptorProtein Kinase Inhibitorshepatocellular carcinomaIFN-γPD-1/PD-L1peripheral cytotoxic lymphocytestyrosine kinase inhibitor

Identifiers

PMID41766908
PMCPMC12935948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.